These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 16434454)

  • 1. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions.
    Pagán YL; Srouji SS; Jimenez Y; Emerson A; Gill S; Hall JE
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1309-16. PubMed ID: 16434454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.
    Arroyo A; Laughlin GA; Morales AJ; Yen SS
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3728-33. PubMed ID: 9360532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome.
    Srouji SS; Pagán YL; D'Amato F; Dabela A; Jimenez Y; Supko JG; Hall JE
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1347-52. PubMed ID: 17264175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of GnRH-stimulated LH release to episodic LH secretion and baseline endocrine-metabolic measures in women with polycystic ovary syndrome.
    Patel K; Coffler MS; Dahan MH; Malcom PJ; Deutsch R; Chang RJ
    Clin Endocrinol (Oxf); 2004 Jan; 60(1):67-74. PubMed ID: 14678290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics.
    Hayes FJ; Taylor AE; Martin KA; Hall JE
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2343-9. PubMed ID: 9661606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome.
    Taylor AE; McCourt B; Martin KA; Anderson EJ; Adams JM; Schoenfeld D; Hall JE
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2248-56. PubMed ID: 9215302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Pastor CL; Griffin-Korf ML; Aloi JA; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 1998 Feb; 83(2):582-90. PubMed ID: 9467578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
    Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
    J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of the gonadotrophin releasing hormone (GnRH) test in the diagnosis of polycystic ovary syndrome (PCOS).
    Lewandowski KC; Cajdler-Łuba A; Salata I; Bieńkiewicz M; Lewiński A
    Endokrynol Pol; 2011; 62(2):120-8. PubMed ID: 21528473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women.
    Holte J; Bergh T; Gennarelli G; Wide L
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):473-81. PubMed ID: 7955458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback.
    Hayes FJ; Seminara SB; Decruz S; Boepple PA; Crowley WF
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3027-35. PubMed ID: 10999781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of gonadotropin secretion: implications for polycystic ovary syndrome.
    McCartney CR; Eagleson CA; Marshall JC
    Semin Reprod Med; 2002 Nov; 20(4):317-26. PubMed ID: 12536355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness.
    van den Berghe G; Weekers F; Baxter RC; Wouters P; Iranmanesh A; Bouillon R; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3217-26. PubMed ID: 11443192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women.
    Couzinet B; Young J; Kujas M; Meduri G; Brailly S; Thomas JL; Chanson P; Schaison G
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4191-6. PubMed ID: 10566671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
    Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
    Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.